

Review Paper

Cognitive decline and brain pathology in aging – need for a dimensional, lifespan and systems vulnerability viewKRISTINE B WALHOVD,^{1,2} ANDERS M FJELL^{1,2} and THOMAS ESPESETH^{3,4}¹*Research Group for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Norway*²*Department of Physical medicine and rehabilitation, Unit of neuropsychology, Oslo University Hospital, Norway*³*Department of Psychology, University of Oslo, Norway*⁴*Norwegian Centre for Mental Disorders Research (NORMENT), and KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Norway*Walhovd, K. B., Fjell, A. M. & Espeseth, T. (2014). Cognitive decline and brain pathology in aging – need for a dimensional, lifespan and systems vulnerability view. *Scandinavian Journal of Psychology* 55, 244–254.

Changes in brain structure and activity as well as cognitive function are commonly seen in aging. However, it is not known when aging of brain and cognition starts, and how much of the changes observed in seemingly healthy older adults that can be ascribed to incipient neurodegenerative disease. Recent research has yielded evidence that the borders between development and aging sometimes can be fuzzy, as can the borders between dementing disease and normal age changes. In this review, we argue that many factors affecting cognitive decline and dementia represents quantitative rather than qualitative differences in characteristics that commonly exist in the population. Further, factors known to affect brain and cognition in aging will often do so through a life-long accumulation of impact, and does not need to be specific to aging. And finally, a host of environmental and genetic factors and their interplay determine optimal aging, leaving room for potential for environmental interventions to affect the outcome of the aging process. Together, we argue that these factors call for a dimensional rather than categorical, lifespan rather than aging, and multidimensional systems-vulnerability rather than simple “hypothetical biomarker” model of age-associated cognitive decline and dementia. This has implications for how we should view lifespan trajectories of change in brain and cognitive function, and how we can study, prevent, diagnose and treat age-associated cognitive deficits.

Key words: Brain, cognition, dimensional view, systems vulnerability, lifespan, aging, Alzheimer’s disease, MRI.

Kristine B Walhovd, Department of Psychology, Pb. 1094 Blindern, 0317 Oslo, Norway. Tel: +47 22 84 51 30; fax: +47 22 84 50 01; e-mail: k.b.walhovd@psykologi.uio.no

INTRODUCTION

Psychological and behavioral adjustment of the individual throughout life is the result of a dynamic interaction between endogenous and exogenous influences, and is profoundly linked to neural substrates undergoing change. Cognitive functioning relates to structural and functional brain characteristics both in healthy aging and in aging-related disorders, for example, mild cognitive impairment (MCI) and dementing disorders, both of probable Alzheimer type (AD) and others, such as vascular dementia. Several brain areas have been implicated, and the exact neural foundations vary according to the nature of pathology. However, there also appear to be similarities across clinical conditions and healthy aging, with structural differences and decline repeatedly having been identified in medial temporal, parietal and prefrontal areas, including, but not limited to, hippocampal, entorhinal, parahippocampal, retrosplenial, posterior and anterior cingulate, medial and lateral prefrontal cortices. These areas are central in the default mode network (DMN), crucial to navigation in time and space, including episodic memory and imagery, which appear disturbed in a number of conditions involving cognitive decline. In addition, there may likely be cerebral cortical differences specific to distinct types of cognitive deficits and disease. Moreover, current data point to vulnerabilities of the individual not exclusively being “turned on” in aging, but rather accumulating across the lifespan, as a result of continuous interactions between endogenous and exogenous factors.

In this review, we assemble current empirical investigations to show that many features contributing to determine cognitive decline and dementing disease are likely: (1) not unique to pathology, but rather represent quantitative differences along a continuum, characteristics that are also present in broader populations in aging; (2) not unique to aging, but rather represent features which have been present to some degree in early, perhaps even fetal life; and (3) not necessarily resistant to influence from and interactions with a host of environmental factors.

Together, we argue that these factors call for a dimensional rather than categorical, lifespan rather than aging, and multidimensional systems-vulnerability rather than simple “hypothetical biomarker” (Jack, Knopman, Jagust *et al.*, 2013; Jack, Knopman, Jagust *et al.*, 2010) model of age-associated cognitive decline and dementia. We argue that a neurobiological relationship between lighter symptoms of cognitive problems and dementing disorder is more evident than often emphasized. This has implications for the view of lifespan trajectories of change in brain and cognition, and how to study, prevent, diagnose and treat age-associated cognitive deficits.

CONTINUOUS INFLUENCES ACROSS THE LIFESPAN

Recent literature makes clear that a number of cognitive and brain features observed in aging can in fact be predicted by early life characteristics, exerting continuous influences across the lifespan. The most obvious example of this might be observed for

cognitive abilities, for which cohort data spanning several decades now exist. For instance, remarkable predictive validity of intelligence tests at age 11 for cognitive performance at age 90 years has been observed (Deary, Pattie & Starr, 2013). Moreover, it has become clear that a number of other typical outcome measures in studies of aging, in fact may also be predicted by events and mechanisms exerting their influence very early in life, even at the embryonic stage. Yet, currently, a coherent lifespan perspective is largely lacking in aging and AD research. When investigating predictors of brain volumes in aging and neurodegenerative disease, it is our opinion that too little attention is given to the fact that one is studying an organ that reaches above 80% of adult volume in infancy, and virtually maximal size (>95%) before school age (Dekaban, 1978). It follows from this state of affairs that a strong, and possibly the greatest, predictor of neuroanatomical characteristics in aging is found at a very early stage of life. For instance, birth weight has been found to predict neuroanatomical volumes and cortical surface area in later childhood, adolescence and early adulthood (Walhovd, Reinvang, Rootwelt & Espeseth, 2012). Moreover, genetic variants found to be associated with brain and cognition in aging and AD, have recently been observed to exert major influences also in children. A prominent example may be variants of the fat mass and obesity (FTO) –associated gene. For this gene, commonly occurring variation has been associated with reduced brain volumes in healthy aging (Ho, Stein, Hua *et al.*, 2010) as well as risk of AD (Reitz, Mayeux, Luchsinger, Group, N.-L. N. F. S. & Alzheimer's Disease Neuroimaging, 2012). Recently, it was shown that that FTO-variance was associated with smaller brain volumes also in adolescents (Melka, Gillis, Bernard *et al.*, 2013), meaning that the reductions observed in aging may be present throughout life, also at the embryonic stage. Likewise, APOE ϵ 4 carriers were recently found to show reduced temporal lobe volumes at birth (Knickmeyer, Wang, Zhu *et al.*, 2013), as discussed further below. In sum, current data point to many risk factors associated with aging and neurodegenerative disease being there from the beginning. They may represent stable risk factors, and sometimes have accumulative consequences throughout the lifespan. If we were able to take these early influences into account in a more precise way, we might be more successful at identifying whatever other, and important, even if potentially modest, influences exist in aging.

Cross-sectional vs. longitudinal studies for detection of life-span trajectories

Changes in cognitive function or brain activity or structures cannot be definitely determined based on cross-sectional data alone (Raz & Lindenberger, 2010), as cross-sectional studies are potentially vulnerable to cohort-effects and selection bias. In some cases, cross-sectional estimates diverge substantially (Raz, Lindenberger, Rodrigue *et al.*, 2005), or even oppose, longitudinal observations (Nyberg, Salami, Andersson *et al.*, 2010; Raz & Lindenberger, 2011). Some evidence suggests that cross-sectional studies may underestimate the extent of regional brain shrinkage in some regions (Raz *et al.*, 2005). Different procedures can be undertaken to reduce the possible influence of cohort effects. For instance, in studies of brain structure, it is

common practice to correct the data for intracranial volume (ICV). The main determinant of ICV is the lifetime maximum size of the brain, and ICV-corrections thus have the potential to reduce impact of cohort effects (Walhovd, Westlye, Amlien *et al.*, 2011).

Although a longitudinal design often is preferable, some of the inherent problems of mapping life-span trajectories associated with cross-sectional examinations are not easily resolved with longitudinal data. Longitudinal examinations of brain activity or structure over decades are not feasible. Adding to this are methodological problems such as attrition and selective recruitment. The much higher costs associated with longitudinal vs. cross-sectional studies in terms of effort and financing have caused many longitudinal studies to be limited in age-span, sample size and number of follow-ups, especially when it comes to brain imaging. To some degree, combined cross-sectional and longitudinal designs can alleviate the concerns raised above. An ideal approach to reproduce the dynamic process of change would be longitudinal studies with high density of measures and assessment of multiple time windows across the life span (Raz *et al.*, 2010; Raz & Lindenberger, 2011). As of yet, we know of no studies including brain imaging data using such a design from childhood and into old age.

ARE AD-SUSCEPTIBILITY GENES RELATED TO GENERAL LIFE-LONG INFLUENCES?

Heritability for sporadic late onset AD is estimated to be 60–80%, motivating an intense search for genetic variants that confer risk for AD for more than three decades (Bertram, McQueen, Mullin, Blacker & Tanzi, 2007; Gatz, Reynolds, Fratiglioni *et al.*, 2006). AD is a genetically complex disorder in which many different genes, each with small estimated effect, is likely to underlie the heritability (Bertram *et al.*, 2007). There are as of October 2013 695 genes and 2,973 polymorphisms registered in the Alzgene database (www.alzgene.org) and the number is steadily increasing as new large-scale genome-wide association scans are conducted. The top 10 association list includes *APOE*, *BINI*, *CLU*, *ABCA7*, *CRI*, *PICALM*, *MS4A6A*, *CD33*, *MS4A4E*, *CD2AP* – all of which, with the exception of *APOE*, have odds ratios (OR) that barely deviate from 1 (i.e., deviation = 0.1–0.2). One other likely AD susceptibility gene, *TREM2*, is reported to have OR between 3 and 5 (Guerreiro, Wojtas, Bras *et al.*, 2013; Jonsson, Stefansson, Steinberg *et al.*, 2013), but prevalence of the risk allele is very low (~0.5% or less, depending on the population studied), limiting its usefulness as population level predictor. The most prominent exception to low penetrance in AD genetics is the apolipoprotein E gene (*APOE*) which due to a high OR (~4) and high frequency of the risk variant ϵ 4 (~25%) has a large impact on the prevalence of AD in populations (Bertram, Lange, Mullin *et al.*, 2008; Corder, Saunders, Strittmatter *et al.*, 1993; Genin, Hannequin, Wallon *et al.*, 2011; Raber, Huang & Ashford, 2004; Strittmatter, Saunders, Schmechel *et al.*, 1993). Furthermore, brain and cognition correlates of the *APOE* genetic variants, the specificity of the effects they exert to pathology or old age, and the patterns of interaction with non-genetic factors, have been intensely studied. Similar information is very scarce for the other risk genes.

Effects of Apolipoprotein E on cognition

In the human central nervous system apolipoprotein E (apoE) plays a key role in transport and metabolism of plasma cholesterol and triglycerides, and is involved in synaptogenesis, as well as maintenance and repair of neurons (Mahley, Weisgraber & Huang, 2006; Mauch, Nagler, Schumacher *et al.*, 2001). The *APOE* $\epsilon 4$ allele causes a dose-dependent increase in risk of developing AD (Corder *et al.*, 1993; Strittmatter *et al.*, 1993). It decreases the age of diagnosis (Raber *et al.*, 2004), and is the strongest known genetic risk factor for AD – $\epsilon 4$ homozygosity confers about 14 times increase in lifetime risk compared to $\epsilon 3$ homozygosity, but in an age-dependent manner, with a maximum relative risk of 35 in the age group 60–69 (Genin *et al.*, 2011). The basis of this association is poorly understood owing to the complexity of the underlying pathophysiological mechanisms (Holtzman, Herz & Bu, 2012; Mahley *et al.*, 2006; Verghese, Castellano & Holtzman, 2011). Mahley *et al.* (2006) present two major hypotheses on the relation between *APOE* and neurodegeneration. In the amyloid hypothesis $\epsilon 4$ is suggested to interact with A β to inhibit clearance and/or stimulate deposition of A β (Huang, Weisgraber, Mucke & Mahley, 2004), enhance A β production (Aubert, Barate, Boutigny *et al.*, 2005), and increase lysosomal leakage and apoptotic cell death (Ji, Mullendorff, Cheng, Miranda, Huang & Mahley, 2006). In the neuronal repair hypothesis $\epsilon 4$ is thought to lead to deficient neuronal health through enhanced neuron-specific proteolysis where neurotoxic fragments of the apoE protein is translocated into the cytosol where they lead to cytoskeletal disruption and mitochondrial dysfunction (Mahley *et al.*, 2006). Thus, according to the neuronal repair hypothesis apoE may be related to neuronal health throughout the life span, and may therefore have identifiable physiological phenotypes that are distinct from those caused by pathological processes late in life, such as those suggested by the amyloid hypothesis. *APOE* $\epsilon 4$ interacts strongly with specific age-associated pathogenic factors, most significantly with amyloid accumulation (Liu, Kanekiyo, Xu & Bu, 2013). Amyloid accumulation is absent or infrequent below the age of 50, and remains relatively low even in $\epsilon 4$ carriers until the early 60s (Morris, Roe, Xiong *et al.*, 2010). Therefore, in studies including participants that are middle-aged or younger, amyloid burden is unlikely to bias the results. A large number of studies with non-demented and healthy old participants, healthy middle-aged and young adults, and increasingly also children, indicates that *APOE* genotype affects the structure and function of the normal brain, through roles in neurodevelopment, maintenance and repair.

A large meta-analysis found evidence for memory deficits in $\epsilon 4$ carriers (Wisdom, Callahan & Hawkins, 2011), but the effects size was modest (OR ~ 1.2 for episodic memory, and < 1.2 for other cognitive domains). Many of the studies analyzed may have involved middle-aged and old persons at different stages of prodromal AD, thus challenging the notion that there are measurable cognitive effects of $\epsilon 4$ in healthy samples, at least as assessed with standard psychometric batteries. In a recent structural equation model study Yu, Boyle, Leurgans, Schneider & Bennett (2014) tested whether they could identify direct effects of $\epsilon 4$ on decline in performance on two cognitive components,

episodic memory or nonepisodic cognition as constructed from psychometric battery of tests, or whether $\epsilon 4$ effects were mediated by pathogenic factors such as amyloid β loads, tau tangle densities, presence of cortical Lewy bodies, or macro- or micro infarcts. The results showed that there were no direct effects of $\epsilon 4$ on decline on either episodic memory or nonepisodic cognition after accounting for these pathogenic factors. Studies focusing on tailor-made attention and working memory tasks with middle-aged participants have reported significantly poorer performance for $\epsilon 4$ carriers (Espeseth, Greenwood, Reinvang *et al.*, 2006; Greenwood, Lambert, Sunderland & Parasuraman, 2005; Negash, Greenwood, Sunderland *et al.*, 2009; Reinvang, Winjevoll, Rootwelt & Espeseth, 2010; Rosen, Bergeson, Putnam, Harwell & Sunderland, 2002). These findings are promising but effects sizes are relatively modest (ORs ~ 1.5). In children and young adults both adverse and protective effects have been reported. Han & Bondi (2008), among others, have suggested that the relation between $\epsilon 4$ and cognitive performance across the life span can be characterized as an example of antagonistic pleiotropy – that $\epsilon 4$ may have different effects on fitness across the life span. A meta-analysis including 20 studies in which participants were between 5 and 35 years of age found no support for this hypothesis as no effect sizes reliably differed from zero (Ihle, Bunce & Kliegel, 2012). However, it is still possible that $\epsilon 4$ may have protective effects in children under adverse environmental circumstances, such as in Brazilian shanty town children who showed less diarrhea and accompanying impairments in cognitive development (Oria, Costa, Lima, Patrick & Guerrant, 2009; Oria, Patrick, Zhang *et al.*, 2005), and better cognitive responses to micronutrient supplementation (Mitter, Oria, Kvalsund *et al.*, 2012).

Effects of Apolipoprotein E on brain structure and activity

MRI and PET studies provide stronger support for effects of $\epsilon 4$ in non-demented individuals. FDG-PET studies with young adults (i.e., in their 20s and 30s) have shown reduced cerebral glucose metabolism for $\epsilon 4$ carriers in posterior cingulate, parietal, temporal, and prefrontal cortex (Reiman, Chen, K., Alexander *et al.*, 2004). Effects were in the same regions found for AD patients and older $\epsilon 4$ carriers, but were quantitatively smaller (Reiman, Caselli, Chen, Alexander, Bandy & Frost, 2001; Reiman, Caselli, Yun *et al.*, 1996).

Based on an MRI study, thinner entorhinal cortices were reported for adolescent $\epsilon 4$ carriers (Shaw, Lerch, Pruessner *et al.*, 2007). Many of the participants underwent multiple scans and the neuroanatomical effects of *APOE* genotype seemed to be fixed over the age-range examined. In a recent structural MRI study of 269 neonates, Knickmeyer *et al.* (2013) observed decreased gray matter volume in the temporal lobes, including the hippocampus, and increased parietal lobe volumes in $\epsilon 4$ heterozygous babies compared to $\epsilon 3$ homozygotes. Dean, Jerskey, Chen *et al.* (2014) tested $\epsilon 4$ -related differences in white matter myelin water fractions (MWF) and gray matter volumes (GMV) in 162 healthy infants aged 2 to 25 months and found reduced MWF and GMV in precuneus, posterior/middle cingulate, lateral temporal, and medial occipitotemporal regions for $\epsilon 4$ carriers. Alexander, Bergfield, Chen *et al.* (2012) found a pattern of gray

matter reduction in $\epsilon 4$ carriers ($N = 14$, age 26–45) involving bilateral frontal, anterior cingulate, parietal, and lateral temporal cortices with correlated volume increases in the hippocampal region. In a study of morphometric variation in middle-aged and older-age individuals, Espeseth, Westlye, Fjell *et al.* (2008) found that middle-aged $\epsilon 4$ carriers had a thicker cortex than non-carriers in several frontal and temporal areas in both hemispheres, but showed a steeper estimated age-related decline in adjacent areas. Upon comparison of the $\epsilon 4$ -specific negative age-correlations with previously published patterns of thinning in normal aging and AD, they concluded that $\epsilon 4$ may function to accelerate thinning in areas found to decline in normal aging (medial prefrontal and pericentral cortex), but also to initiate thinning in areas associated with AD and amyloid β aggregation (occipitotemporal and basal temporal cortex). A follow up study by Espeseth, Westlye, Walhovd *et al.* (2012) showed that cortical thickness in the selected regions was associated with attention performance and amplitude of attention-related ERP (event-related potential) components.

Trachtenberg, Filippini, Ebmeier, Smith, Karpe and Mackay (2012) recently performed an analysis on resting-state networks (RSNs), including medial and lateral visual, sensorimotor, auditory, DMN, an “executive control network”, right and left frontoparietal networks, and anterior and posterior hippocampal networks in 77 healthy subjects aged 32–55 years. *APOE* genotype affected the anterior and posterior hippocampal networks, the auditory network, and the left frontoparietal network. Intriguingly, functional integration was similar in $\epsilon 2$ and $\epsilon 4$ carriers, but both groups differed significantly from $\epsilon 3$ homozygotes. The authors concluded that in healthy adults, *APOE* genotype affects the differentiation of functional brain networks independently of the *APOE*-related increased risk of AD, and may instead reflect a functional role of different apoE isoforms during neurodevelopment. The observations of alterations in patterns of functional connectivity in $\epsilon 4$ carriers may be indicative of changes in white matter microstructural integrity. Several DTI studies have documented decreased diffusion anisotropy in $\epsilon 4$ carriers (Heise, Filippini, Ebmeier & Mackay, 2011; Honea, Vidoni, Harsha & Burns, 2009; Persson, Lind, Larsson *et al.*, 2006) possibly indicating less coherent fiber architecture or altered microstructural integrity. Heise *et al.* (2011) compared younger (age 20–35) with older (age 50–78) subjects, but concluded that there was no evidence of age group by *APOE* interactions on any of the DTI measures. Westlye, Reinvang, Rootwelt and Espeseth (2012) studied a healthy sample ($N = 203$) with a wide age distribution (21–70 years) and showed an age-independent increase in radial diffusivity in $\epsilon 4$ carriers. As previously reported by Trachtenberg *et al.* (2012) on RSNs, similar changes were observed in $\epsilon 2$ carriers. $\epsilon 2$ has been reported to have a protective effect with regards to the development of AD (Corder *et al.*, 1993). Thus, when effects on the brain’s functional and structural connectivity are similar for $\epsilon 2$ and $\epsilon 4$, and is present from young adulthood, this may suggest that effect of *APOE* genotype on white matter microstructure and RSNs is independent of its effect on AD risk.

Several studies reviewed above converge on a significant impact of *APOE* on brain morphology. The evidence further suggests that the effects may already be present at birth, and that *APOE* may also modulate the rate of brain aging. In a recent

review of effect of *APOE* genotype in aging and early AD (Reinvang, Espeseth & Westlye, 2013), we concluded that these results are not strongly influenced by presence of amyloid β , either because it has been explicitly controlled for or because of the relatively young age of participants. The findings reviewed indicate that $\epsilon 4$ is a vulnerability factor and not a pathogenic factor at ages where cerebral diseases or injuries are infrequent. This is not to deny that pathogenic factors that interact with *APOE* genotype may have an impact in younger groups, but their frequency or intensity is not sufficient to result in an interaction of *APOE* genotype with age, suggesting that the unique genotypic effects on the various biological and brain phenotypes are relatively invariant with age in healthy subjects. However, the frequency of cerebral injuries are likely to increase with age even in non-demented samples, and when these cannot be identified and controlled for, one may observe increased effects of $\epsilon 4$ with age. Reduced effects of $\epsilon 4$ in high age have also been observed, both in healthy (Espeseth *et al.*, 2006; 2012; Small, Rosnick, Fratiglioni & Backman, 2004) and AD (Chang, Fennema-Notestine, Holland *et al.*, 2013; Farrer, Cupples, Haines *et al.*, 1997) samples, potentially due to sampling error. Our conclusion differs from those of earlier reviews and meta-analyses (Cherbuin, Leach, Christensen & Anstey, 2007; Wisdom *et al.*, 2011), possibly because these studies comprised mainly older participants who may have been pre-symptomatic and had unknown amyloid status. It also differs from a strict version of the cascade model of Jack *et al.* (2010, 2013). Amyloid β is clearly a highly significant pathological factor at initial stages of disease but there is also a high degree of diversity of *APOE*-related pathological mechanisms, affecting the rate and biomarker profile of clinical development. Furthermore, subtle MR and cognitive markers are detectable early in the development of the pathophysiological process that renders $\epsilon 4$ carriers vulnerable to MCI and AD, but they are not only watered-down versions of the changes seen in clinical AD, such as hippocampal atrophy and memory deficit. The conclusion is consistent with theories of AD development allowing for heterogeneous mechanisms, such as the one proposed by Herrup (2010).

Other genetic predictors of AD

As compared to *APOE*, very few translational studies have so far been reported for the other top ten candidates. Some evidence is available for *CLU*, *CRI*, and *PICALM*, which were shown to be associated with AD in two large genome-wide association studies (GWAS) in 2009 (Harold, Abraham, R., Hollingworth *et al.*, 2009; Lambert, Heath, Even *et al.*, 2009). Bralten, Franke, Arias-Vasquez (2011) investigated *CLU*, *CRI*, and *PICALM* in a MRI study aiming to reveal genetic variant effects on voxel-based morphometry assessed integrity of the entorhinal cortex and hippocampus in two samples ($n = 430$ and $n = 492$, respectively) consisting of healthy young individuals aged 18–36 years. They found reduced gray matter volume in the entorhinal cortex for *CRI* rs6656401 A allele carriers in both samples. Erk, Meyer-Lindenberg, Opitz von Boberfeld *et al.* (2011) showed that healthy young participants (mean age ~31 years) had altered functional coupling of the hippocampus in carriers of the risk variant for *CLU* rs11136000 (C allele) during a fMRI

memory task. This effect was independent of *APOE* genotype. In a DTI study with 400 young participants (Mean age = 23.6 years) Braskie, Jahanshad, Stein *et al.* (2011) found reduced fractional anisotropy (FA) in splenium of the corpus callosum, the fornix, cingulum, and superior and inferior longitudinal fasciculi for C allele carriers of the same *CLU* SNP.

A rare missense mutation in triggering receptor expressed on myeloid cells 2 (*TREM2*) was very recently shown to be associated with AD, but has generated much interest because the effect size appears to be comparable to that of *APOE* (Bertram, Parrado & Tanzi, 2013; Guerreiro & Hardy, 2013; Guerreiro *et al.*, 2013; Jonsson *et al.*, 2013; Jonsson & Stefansson, 2013). *TREM2* variants have been reported to be associated with autosomal recessive form of early-onset dementia with bone cysts and consequent fractures (Paloneva, Mandelin, Kiialainen *et al.*, 2003), frontotemporal dementia and with leukodystrophy (Guerreiro & Hardy, 2012). Jonsson *et al.* (2013) showed that non-demented *TREM2* mutation carriers had reduced performance on the Cognitive Performance Scale. Furthermore, this effect seemed to accelerate with age (increase from age around 80 to late 90s), although this effect was measured on only 53 carriers in total, and no formal gene by age interaction was reported. Since no interaction was reported and the age range was limited to old age, it is not clear whether *TREM2* is most accurately defined as a genetic marker for cognitive performance as such, or for cognitive aging. Furthermore, because of the high age of the participants and evidence of cognitive impairment, it is not clear whether *TREM2* is best categorized as a gene involved in normal or pathological states. Similarly, using tensor-based morphometry, Rajagopalan, Hibar and Thompson (2013) recently reported effects of rs9394721, a close proxy for the AD risk variant rs75932628, on temporal lobe atrophy over a 24-month period. They reported that *TREM2* mutation carriers lost 1.4–3.3% more tissue than noncarriers in a pattern that is similar to the profile of AD. Mutation carriers also had smaller hippocampi, poorer cognitive performance, and elevated levels of p-tau181p. Interestingly, a recent GWAS of cerebrospinal fluid tau levels revealed a marker within the *TREM* region (Cruchaga, Kauwe, Harari *et al.*, 2013). However, both the carrier and noncarrier groups consisted of a mixture of healthy non-demented participants, MCI and AD, and no group by genotype interaction was reported, making it difficult to verify whether the effects were specific to, or at least larger, in the AD group.

What do we know about the genetics of AD?

In conclusion, AD is not only polygenic, the genes associated with AD are also pleiotropic. *APOE* is common, exerts a large effect on risk for AD, and a range of other more or less related phenotypes. *APOE* exerts effects over the whole life span, not only in relation to pathological processes, or age-related cognitive decline, and interacts with non-genetic/environmental factors. Less is known about other AD susceptibility genes such as *CLU*, *CRI*, *PICALM*, and *TREM2*, but it seems likely all of them have pleiotropic effects, and variability in at least the three former genes also exerts effects on brain morphometric properties and task-related functional coupling at young ages (at least as early as young adulthood), before significant amyloid β

burden. Less is known about gene by environment interactions for these. Thus, it seems reasonable to conclude that extant research on five of the strongest genetic predictors of AD, effects are not specific to pathology, are not specific to old age, and are likely to be modifiable by environmental factors. This pattern of result supports a dimensional, life span, and systems vulnerability view on cognitive decline brain pathology in aging, which we will now discuss in more detail.

A DIMENSIONAL, SYSTEMS-VULNERABILITY VIEW OF AGING VS. DEMENTIA: THE SAMPLE CASE OF ALZHEIMER'S DISEASE

Incidence of people with AD increases sharply after 60 years (Kawas, Gray, Brookmeyer, Fozard & Zonderman, 2000), and symptoms of AD and symptoms of "normal aging" are overlapping. Disruption of episodic memory function (Koivisto, Reinikainen, Hanninen *et al.*, 1995; Nyberg, Lovden, Riklund, Lindenberger & Backman, 2012), brain atrophy (Driscoll, Davatzikos, An *et al.*, 2009; Fjell, Walhovd, Fennema-Notestine *et al.*, 2009; Raz *et al.*, 2005) and accumulation of amyloid protein (Morris *et al.*, 2010) are found in AD patients as well as in many presumably healthy elderly. As shown above, several genes related to AD risk seem to impact brain and cognition also in non-demented and early in life. Even though few would argue that AD is not a disease distinct from aging, many researchers have proposed that to understand AD, we must understand its relationship to aging (Herrup, 2010). Although less commonly argued, the statement can also be reversed: Understanding why aging is the major risk factor for AD may help us understand brain aging itself. Thus, a systems vulnerability approach to aging and AD, where we try to understand why certain brain regions and neural networks are vulnerable to different detrimental influences (W. Jagust, 2013), may be a more promising approach than focusing on specific diseases, conditions or single etiologies (Khachaturian, 2011). This is not uncontroversial, however, as for instance the popular 'dynamic biomarker model' assumes that AD always starts with deficient processing of beta-amyloid (Jack *et al.*, 2013; Jack *et al.*, 2010), while others argue that AD may be driven by factors less related to aging per se, and should be studied separately from normal aging (Nelson *et al.*, 2011). Both these examples go against a systems-vulnerability view of aging and AD.

What is normal aging?

On one hand, there is a discussion of whether AD should be understood with a basis in normal aging. On the other hand, there is also a discussion of what *normal aging is*. Do pure age-related brain changes exist in isolation from the first stages of progressive degenerative conditions? As dementias like AD are associated with increased rates of brain atrophy (Davatzikos, Xu, An, Fan & Resnick, 2009; Jack *et al.*, 2013; Jack *et al.*, 2010) and subtle cognitive symptoms (Elias *et al.*, 2000) years before diagnosis, cases with undetected disease in presumably normal samples can lead to erroneous inferences about decline in brain structure and function and cognitive abilities in normal aging (Burgmans *et al.*, 2009; Sliwinski & Buschke, 1999).

Interestingly, it is also possible that the opposite problem exists – that very high-functioning elderly are over-represented in research samples and thus yield an overly optimistic picture of brain and cognition in higher age (Nyberg *et al.*, 2010).

There are no easy solutions to the problems with undetected dementia and sampling problems described above. However, we believe recent research has made a strong case that changes in brain and cognitive function characterize normal aging – independently of AD, the most common neurodegenerative disease. Even though the overall pattern of brain changes can be used to differentiate normal aging from AD (Driscoll *et al.*, 2009; Fjell, Amlie, Westlye *et al.*, 2010; McEvoy, Fennema-Notestine, Roddey *et al.*, 2009; McEvoy, Holland, Hagler *et al.*, 2011), brain regions affected by AD nevertheless show decline also in normal aging. Entorhinal cortex and the hippocampus are especially vulnerable to AD disease pathology, including neurofibrillary tangles, atrophy and other types of AD-pathology (Braak & Braak, 1985, 1991; Jack *et al.*, 1997; McDonald *et al.*, 2009; Van Hoesen, Hyman & Damasio, 1991). These regions are among the most vulnerable in normal aging, with accelerating decline from about 60 years (Driscoll *et al.*, 2009; Fjell, Walhovd, K. Fennema-Notestine *et al.*, 2009; Fjell, Westlye, Grydeland *et al.*, 2012; Pfefferbaum, Rohlfing, Rosenbloom, Chu, Colrain & Sullivan, 2013; Raz, Ghisletta, Rodrigue, Kennedy & Lindenberger, 2010; Walhovd *et al.*, 2011). This does not mean that atrophy in these regions cannot be used to aid classification of patients and in prediction progression of the disease (Fjell, Walhovd, Fennema-Notestine *et al.*, 2010), but rather that decline is not restricted to degenerative conditions.

Several lines of evidence support this view. Resnick and colleagues found significant reductions in brain volume in all cortical lobes in very healthy participants who experienced no medical condition or cognitive impairment up to ten years after the initial examination, and argued that the uniformity of tissue loss across individual participants indicated that these were not pathological changes associated with preclinical dementia (Driscoll *et al.*, 2009; Resnick, Pham, Kraut, Zonderman & Davatzikos, 2003). Fjell *et al.* demonstrated reductions in the temporal lobe, including the hippocampus and the entorhinal cortex, in groups of elderly with very low probability of having incipient AD (Fjell, McEvoy, Holland *et al.*, 2013; Fjell *et al.*, 2012). Subgroups of clinically and cognitively super-stable, as well as groups of elderly who were amyloid negative, negative for APOE ϵ 4 and with only minute change in episodic memory scores, all showed temporal lobe reductions in thickness or volume. Importantly, the brain changes also correlated with changes in scores on tests of episodic memory, indicating that these brain changes, although likely not related to AD-processes, were not completely benign. These results demonstrate that significant entorhinal and hippocampal atrophy can be detected in groups of elderly at very low risk of AD defined by clinical neuropsychological, genetic and biomarker criteria (Fjell *et al.*, 2013). An independent study also identified small hippocampal volumes in amyloid negative elderly (Knopman, Jack, Wiste *et al.*, 2012). Thus, age-related changes that cannot be ascribed to undetected AD are very likely, even in AD-prone regions. Of course, there is accumulation of other neurodegenerative conditions besides AD in aging. However, the uniformity of the anatomical

distribution of atrophy makes it in our view unlikely that these changes are driven mainly by specific, disease-related neurodegenerative processes.

Why are brain regions vulnerable to AD also vulnerable to normal aging?

These findings bring us over to a pertinent and very interesting question: Why are AD-prone areas especially atrophic in normal aging? A popular view is that brain regions characterized by high degree of neuroplasticity are especially vulnerable both to aging and AD (Bufill, Blesa & Augusti, 2013; Bufill & Carbonell, 2004; Mesulam, 1999; Neill, 1995, 2012; Rapoport & Nelson, 2011). This is in line with a systems vulnerability view. In the aging brain, neuroplasticity, rather than being adaptive, could contribute to neuropathology. While, as argued above, a number of genetic candidates of focus in brain aging may in fact exert their influence also early in the lifespan, some would argue that there are also cases of antagonistic pleiotropy, where evolutionary changes beneficial for survival in youth increase the vulnerability to diseases in aging (but see Ihle *et al.*, 2012). Data obtained to date show that many genes associated with AD at some levels, including APOE4, are involved in synaptic plasticity (Bufill *et al.*, 2013). Human specific evolutionary changes in neuroplastic potential could therefore have occurred to allow optimal behavioral flexibility, and maladaptive interaction between this human specific evolutionary brain adaptation and age-related changes can be responsible for cognitive decline in aging (Neill, 2012). Brain regions with highly neuroplastic long axonal connections are highly affected in AD, including parts of the entorhinal cortex, hippocampus and association neocortex (Rapoport & Nelson, 2011). Potential for neuroplasticity in elderly, with performance gains and accompanying changes in gray matter density (Boyke, Driemeyer, Gaser, Buchel & May, 2008), cortical thickness (Engvig, Fjell, Westlye *et al.*, 2010) and white matter microstructure (Engvig, Fjell, Westlye *et al.*, 2012), has been shown, demonstrating that humans have a high level of neuroplasticity retained in late life. This neuroplastic system is particularly responsive to environmental and internal factors. Neurons in certain association areas retain juvenile characteristics into adulthood, for example, increased expression of genes related to synaptic activity and plasticity, incomplete myelination and elevated aerobic metabolism, which likely cause an increase in oxidative stress in these neurons (Bufill *et al.*, 2013). The cost of such maintained plasticity may be increased vulnerability to factors which can trigger cognitive decline (Bufill *et al.*, 2013).

The medial temporal lobes are high-vulnerability areas for the impact of both normal aging and AD. Together with posterior parietal association cortices, for example, the precuneus, these regions are critical in learning and memory, with high demands for neuroplasticity (Aimone, Deng & Gage, 2010; Deng, Aimone & Gage, 2010). For instance, it has been suggested that altered neurogenesis in the hippocampus is an early critical event in AD (Mu & Gage, 2011). Neurogenesis in the adult human brain is restricted (Rakic, 2004) and unlikely to be a main factor in the changes in brain and cognition associated with aging. However, mechanisms such as dendritic spine plasticity (Benavides-Piccione,

Fernaund-Espinosa, Robles, Yuste & Defelipe, 2013; Bloss, Janssen, Ohm *et al.*, 2011; Esiri, 2007; Freeman, Kandel, Cruz *et al.*, 2008; Jacobs, Driscoll & Schall, 1997) may be critical in aging, likely of importance for long-term memory (Sanders, Cowansage, Baumgartel & Mayford, 2012). Thus, it may be that certain brain regions are characterized by increased demands for plasticity throughout life, and that this makes them especially vulnerable to subtle lesions and accumulating pathology. This could be one common denominator for brain atrophy and memory problems in aging and AD.

The role of amyloid in normal aging

The default mode network consists of a set of brain regions vulnerable to both normal aging and AD, especially the medial parietal and posterior cingulate/ retrosplenial, lateral temporal and temporo-parietal cortices. Interestingly, there is anatomical overlap between deposition of amyloid as measured by PiB PET *in vivo* and the default mode network of the brain. Unfortunately, the role played by amyloid in normal aging and in the transition from normal aging to neurodegeneration is very poorly understood. Are amyloid-atrophy correlations in cognitively normal elderly always indicative of undetected, AD-related degeneration, or could amyloid be a part of normal aging as well? Rodent research has demonstrated that synaptic and neural activity increases amyloid-beta levels (Bero, Yan, Roh *et al.*, 2011; Cirrito, Yamada, Finn *et al.*, 2005). If the same mechanisms exist also in humans, it could be that the level of brain activity itself may be causally related to amyloid deposition (Buckner, 2012; Jagust & Mormino, 2011). This theory has some interesting implications. For instance, it has been argued that higher education enables people to maintain cognitive function despite high levels of brain pathology, related to the concept of cognitive reserve (Stern, 2006, 2012; Stern, Albert, Tang & Tsai, 1999). According to the activity-dependent amyloid accumulation view, however, higher education itself could lead to the build-up of amyloid pathology through enhancement of life-long mental activity.

Although the theory of accumulation of amyloid in specific cortical regions as a result of higher levels of cognitive activity has received a lot of recent attention, there are difficulties: First, mental activity in the form of cognitive interventions (Engvig *et al.*, 2010; Zatorre, Fields & Johansen-Berg, 2012) and accumulated mental activity (Valenzuela, Sachdev, Wen, Chen & Brodaty, 2008) have positive effects on brain and cognition in elderly, and has been shown to be inversely related to amyloid deposition (Landau, Marks, Mormino *et al.*, 2012), but see Members, Brayne, Ince *et al.*, 2010; Vemuri, Lesnick, Przybelski *et al.*, 2012). Second, even if the overlap between DMN and early A β deposition is causally related to the generally high DMN activity (Buckner, 2012; Jagust & Mormino, 2011), it is yet not obvious whether the life-long pattern of brain activity is higher in the areas with higher A β depositions, for example, the medial posterior parietal cortex, than in the areas with less, such as the medial temporal lobes or the visual cortex (Mormino, Brandel, Madison *et al.*, 2012; Sojkova, Zhou, Y., An *et al.*, 2011). Finally, there is growing agreement that A β accumulation in sporadic AD is more related to decreased clearance than

increased production (Castellano, Kim, Stewart *et al.*, 2011; DeMattos, Cirrito, Parsadanian *et al.*, 2004; Mawuenyega, Sigurdson, Ovod *et al.*, 2010). Thus, it may not be increased A β production that is the most relevant factor for amyloid deposition, but rather the ability of the brain to keep the A β peptides soluble (Robakis, 2010).

Cognitive reductions in aging – complex causes

In any case, the weak correlations between amyloid level and cognitive function in normal aging suggest that other mechanisms (Hedden, Oh, Younger & Patel, 2013), such as functional compensation (Cabeza, Anderson, Locantore & McIntosh, 2002; Grady, 2012; Park & Reuter-Lorenz, 2009), also impact cognitive ability. According to a compensation view, the magnitude of brain insults that can be accommodated without cognitive decline and progression to AD varies significantly between individuals, and a key to understanding why may be individual differences in neural and cognitive plasticity. Thus, it is important to understand the mechanisms that cause some older adults to develop AD and some to maintain cognitive function in spite of accumulated brain amyloid and other possibly detrimental factors. For instance, the relationship between brain atrophy and amyloid load varies substantially between different groups of people (Fjell, Walhovd, Fennema-Notestine, *et al.*, 2010). We will argue that a key to understand cognitive function in aging and AD, as well as the AD disease mechanisms themselves, is to systematically investigate individual differences in the relationships between the major cognitive, genetic and biological events in aging and AD. One approach would be to directly focus on the relationship between cognitive and brain plasticity on the one hand, and aging- and AD-related biomarkers, including genetics, on the other. The results of such studies may substantially move the limits of our understanding of the relationship between cognitive function and brain integrity in normal aging and the earliest phases of AD. The basis of this approach would need to be a systems vulnerability view, where cognitive changes in normal aging and AD at least to some extent have overlapping causes, and where focus is on the interplay between multiple factors and brain regions more than single etiological factors.

CONCLUSION

In this review, we have tried to show that the factors affecting brain aging often can be traced back to early development, and that modifiers of aging may exert their influence through a life-time. For both genetic and environmental factors, this can be true. This is what we refer to as a lifespan perspective. Further, we have tried to show that on a neurobiological level, the borders between normal aging and neurodegenerative conditions such as AD may not always be clear cut, and that many brain and cognitive symptoms are not unique to dementia. This is what we call the dimensional perspective. Finally, cognitive decline in aging and dementia do not have a single etiology, as there is not one single brain region or system that is affected. Rather, different factors impact brain and cognitive function both in health and disease, and a major aim of contemporary research is to understand what

make the different brain systems vulnerable to all these different factors. This is what we refer to as a systems-vulnerability view. Agreeing with these perspectives will mean a rejection of the common focus of aging as separated from the rest of the life, a revision of the view that changes in brain and cognitive functions in normal aging and AD do not have overlapping causes, and moving away from the search for single etiological factors, for example, amyloid accumulation, as the “big evil” in cognitive reductions in dementias and normal aging.

The project was financed by The Norwegian Research Council (A.M.F., K.B.W., T.E.) and the European Research Council (A.M.F. and K.B.W.).

REFERENCES

- Aimone, J. B., Deng, W. & Gage, F. H. (2010). Adult neurogenesis: integrating theories and separating functions. *Trends in cognitive sciences*, *14*, 325–337.
- Alexander, G. E., Bergfield, K. L., Chen, K., Reiman, E. M., Hanson, K. D., Lin, L., *et al.* (2012). Gray matter network associated with risk for Alzheimer’s disease in young to middle-aged adults. *Neurobiology of Aging*, *33*, 2723–2732.
- Aubert, B., Barate, R., Boutigny, D., Couderc, F., Gaillard, J. M., Hicheur, A., *et al.* (2005). Search for the rare leptonic decay $B \rightarrow \tau \nu$. *Physical Review Letters*, *95*, 041804.
- Benavides-Piccione, R., Fernaud-Espinosa, I., Robles, V., Yuste, R. & Defelipe, J. (2013). Age-based comparison of human dendritic spine structure using complete three-dimensional reconstructions. *Cerebral Cortex*, *23*, 1798–1810.
- Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., *et al.* (2011). Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. *Nature neuroscience*, *14*, 750–756.
- Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., *et al.* (2008). Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. *American Journal of Human Genetics*, *83*, 623–632.
- Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. (2007). Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. *Nature Genetics*, *39*, 17–23.
- Bertram, L., Parrado, A. R. & Tanzi, R. E. (2013). TREM2 and neurodegenerative disease. *New England Journal of Medicine*, *369*, 1565.
- Bloss, E. B., Janssen, W. G., Ohm, D. T., Yuk, F. J., Wadsworth, S., Saardi, K. M., *et al.* (2011). Evidence for reduced experience-dependent dendritic spine plasticity in the aging prefrontal cortex. *The Journal of Neuroscience*, *31*(21), 7831–7839.
- Boyke, J., Driemeyer, J., Gaser, C., Buchel, C. & May, A. (2008). Training-induced brain structure changes in the elderly. *Journal of Neuroscience*, *28*, 7031–7035.
- Braak, H. & Braak, E. (1985). On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina-specific pathology in Alzheimer’s disease. *Acta Neuropathologica*, *68*, 325–332.
- Braak, H. & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathologica*, *82*, 239–259.
- Bralten, J., Franke, B., Arias-Vasquez, A., Heister, A., Brunner, H. G., Fernandez, G. & Rijpkema, M. (2011). CR1 genotype is associated with entorhinal cortex volume in young healthy adults. *Neurobiology of Aging*, *32*(2106), e2107–2111.
- Braskie, M. N., Jahanshad, N., Stein, J. L., Barysheva, M., McMahon, K. L., de Zubicaray, G. I., *et al.* (2011). Common Alzheimer’s disease risk variant within the CLU gene affects white matter microstructure in young adults. *Journal of Neuroscience*, *31*, 6764–6770.
- Buckner, R. L. (2012). The serendipitous discovery of the brain’s default network. *Neuroimage*, *62*, 1137–1145.
- Buflil, E., Blesa, R. & Augusti, J. (2013). Alzheimer’s disease: An evolutionary approach. *Journal of Anthropological Sciences*, *91*, 135–157.
- Buflil, E. & Carbonell, E. (2004). Are symbolic behaviour and neuroplasticity an example of gene-culture coevolution? *Revista de Neurologia*, *39*, 48–55.
- Burgmans, S., van Boxtel, M. P., Vuurman, E. F., Smeets, F., Gronenschild, E. H., Uylings, H. B. & Jolles, J. (2009). The prevalence of cortical gray matter atrophy may be overestimated in the healthy aging brain. *Neuropsychology*, *23*, 541–550.
- Cabeza, R., Anderson, N. D., Locantore, J. K. & McIntosh, A. R. (2002). Aging gracefully: compensatory brain activity in high-performing older adults. *NeuroImage*, *17*, 1394–1402.
- Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B. & Patterson, B. W. *et al.* (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. *Science Translational Medicine*, *3*, 89ra57.
- Chang, Y. L., Fennema-Notestine, C., Holland, D., McEvoy, L. K., Stricker, N. H. & Salmon, D. P. *et al.* (2013). APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer’s disease. *Alzheimer’s & Dementia*, doi: 10.1016/j.jalz.2013.05.1763 [Epub ahead of print].
- Cherbuin, N., Leach, L. S., Christensen, H. & Anstey, K. J. (2007). Neuroimaging and APOE genotype: A systematic qualitative review. *Dementia and Geriatric Cognitive Disorders*, *24*, 348–362.
- Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., *et al.* (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. *Neuron*, *48*, 913–922.
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., *et al.* (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. *Science*, *261*, 921–923.
- Cruchaga, C., Kauwe, J. S., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., *et al.* (2013). GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease. *Neuron*, *78*, 256–268.
- Davatzikos, C., Xu, F., An, Y., Fan, Y. & Resnick, S. M. (2009). Longitudinal progression of Alzheimer’s-like patterns of atrophy in normal older adults: The SPARE-AD index. *Brain*, *132*, 2026–2035.
- Dean, D. C. 3rd, Jerskey, B. A., Chen, K., Protas, H., Thiyyagura, P., Roontiva, A., *et al.* (2014). Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: A cross-sectional imaging study. *JAMA Neurology*, *71*, 11–22.
- Deary, I. J., Pattie, A. & Starr, J. M. (2013). The stability of intelligence From age 11 to age 90 Years: The Lothian Birth Cohort of 1921. *Psychological Science*, *24*, 2361–2368.
- Dekaban, A. S. (1978). Changes in brain weights during the span of human life: Relation of brain weights to body heights and body weights. *Annals of Neurology*, *4*, 345–356.
- DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O’Dell, M. A., Taylor, J. W., *et al.* (2004). ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. *Neuron*, *41*, 193–202.
- Deng, W., Aimone, J. B. & Gage, F. H. (2010). New neurons and new memories: How does adult hippocampal neurogenesis affect learning and memory? *Neuroscience*, *11*, 339–350.
- Driscoll, I., Davatzikos, C., An, Y., Wu, X., Shen, D., Kraut, M. & Resnick, S. M. (2009). Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. *Neurology*, *72*, 1906–1913.
- Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F. & D’Agostino, R. B. (2000). The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. *Archives of Neurology*, *57*, 808–813.
- Engvig, A., Fjell, A. M., Westlye, L. T., Moberget, T., Sundseth, O., Larsen, V. A. & Walhovd, K. B. (2010). Effects of memory training on cortical thickness in the elderly. *Neuroimage*, *52*, 1667–1676.
- Engvig, A., Fjell, A. M., Westlye, L. T., Moberget, T., Sundseth, O., Larsen, V. A. & Walhovd, K. B. (2012). Memory training impacts

- short-term changes in aging white matter: A longitudinal diffusion tensor imaging study. *Human Brain Mapping*, 33, 2390–2406.
- Erk, S., Meyer-Lindenberg, A., Opitz von Boberfeld, C., Esslinger, C., Schnell, K., Kirsch, P., et al. (2011). Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. *Journal of Neuroscience*, 31, 18180–18184.
- Esiri, M. M. (2007). Ageing and the brain. *Journal of Pathology*, 211(2), 181–187.
- Espeseth, T., Greenwood, P. M., Reinvang, I., Fjell, A. M., Walhovd, K. B., Westlye, L. T., et al. (2006). Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. *Cognitive, Affective & Behavioral Neuroscience*, 6, 31–43.
- Espeseth, T., Westlye, L. T., Fjell, A. M., Walhovd, K. B., Rootwelt, H. & Reinvang, I. (2008). Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. *Neurobiology of aging*, 29, 329–340.
- Espeseth, T., Westlye, L. T., Walhovd, K. B., Fjell, A. M., Endestad, T., Rootwelt, H. & Reinvang, I. (2012). Apolipoprotein E epsilon4-related thickening of the cerebral cortex modulates selective attention. *Neurobiology of Aging*, 33(2), 304–322.
- Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*, 278, 1349–1356.
- Fjell, A. M., Amlien, I. K., Westlye, L. T., Stenset, V., Fladby, T., Skinningsrud, A., et al. (2010). CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging. *Neuroimage*, 49, 1820–1830.
- Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., Walhovd, K. B. & Neuroimaging, Alzheimer's Disease (2013). Brain changes in older adults at very low risk for Alzheimer's disease. *Journal of Neuroscience*, 33, 8237–8242.
- Fjell, A. M., Walhovd, K. B., Fennema-Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., et al. (2010). Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. *Cerebral Cortex*, 20, 2069–2079.
- Fjell, A. M., Walhovd, K. B., Fennema-Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., et al. (2009). One-year brain atrophy evident in healthy aging. *Journal of Neuroscience*, 29, 15223–15231.
- Fjell, A. M., Walhovd, K. B., Fennema-Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., et al. (2010c). CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. *The Journal of Neuroscience*, 30, 2088–2101.
- Fjell, A. M., Westlye, L. T., Grydeland, H., Amlien, I., Espeseth, T., Reinvang, I., et al. (2012). Accelerating cortical thinning: Unique to dementia or universal in aging? *Cerebral Cortex*, doi:10.1093/cercor/bhs379 [Epub ahead of print].
- Freeman, S. H., Kandel, R., Cruz, L., Rozkalne, A., Newell, K., Frosch, M. P., et al. (2008). Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, 67, 1205–1212.
- Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., et al. (2006). Role of genes and environments for explaining Alzheimer disease. *Archives of General Psychiatry*, 63, 168–174.
- Genin, E., Hannequin, D., Wallon, D., Slegers, K., Hiltunen, M., Combarros, O., et al. (2011). APOE and Alzheimer disease: A major gene with semi-dominant inheritance. *Molecular Psychiatry*, 16, 903–907.
- Grady, C. (2012). The cognitive neuroscience of ageing. *Nature Reviews Neuroscience*, 13, 491–505.
- Greenwood, P. M., Lambert, C., Sunderland, T. & Parasuraman, R. (2005). Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: Results From the National Institute of Mental Health's BIOCARD study. *Neuropsychology*, 19, 199–211.
- Guerreiro, R. J. & Hardy, J. (2012). TOMM40 association with Alzheimer disease: Tales of APOE and linkage disequilibrium. *Archives of Neurology*, 69, 1243–1244.
- Guerreiro, R. & Hardy, J. (2013). TREM2 and neurodegenerative disease. *New England Journal of Medicine*, 369, 1569–1570.
- Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogava, E., Majounie, E., et al. (2013). TREM2 variants in Alzheimer's disease. *New England Journal of Medicine*, 368, 117–127.
- Han, S. D. & Bondi, M. W. (2008). Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. *Alzheimers & Dementia*, 4, 251–254.
- Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PIC1L associated with Alzheimer's disease. *Nature Genetics*, 41, 1088–1093.
- Hedden, T., Oh, H., Younger, A. P. & Patel, T. A. (2013). Meta-analysis of amyloid-cognition relations in cognitively normal older adults. *Neurology*, 80, 1341–1348.
- Heise, V., Filippini, N., Ebmeier, K. P. & Mackay, C. E. (2011). The APOE varepsilon4 allele modulates brain white matter integrity in healthy adults. *Molecular Psychiatry*, 16, 908–916.
- Herrup, K. (2010). Reimagining Alzheimer's disease: An age-based hypothesis. *The Journal of Neuroscience*, 30, 16755–16762.
- Ho, A. J., Stein, J. L., Hua, X., Lee, S., Hibar, D. P., Leow, A. D., et al. (2010). A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. *Proceedings of the National Academy of Sciences USA*, 107, 8404–8409.
- Holtzman, D. M., Herz, J. & Bu, G. (2012). Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. *Cold Spring Harbor Perspectives in Medicine*, 2, a006312. doi:10.1101/cshperspect.a006312.
- Honea, R. A., Vidoni, E., Harsha, A. & Burns, J. M. (2009). Impact of APOE on the healthy aging brain: A voxel-based MRI and DTI study. *Journal of Alzheimers Disear*, 18, 553–564.
- Huang, Y., Weisgraber, K. H., Mucke, L. & Mahley, R. W. (2004). Apolipoprotein E: Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. *Journal of Molecular Neuroscience*, 23, 189–204.
- Ihle, A., Bunce, D. & Kliegel, M. (2012). APOE epsilon4 and cognitive function in early life: A meta-analysis. *Neuropsychology*, 26, 267–277.
- Jack, C. R. Jr, Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. *Lancet Neurology*, 12, 207–216.
- Jack, C. R. Jr, Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurology*, 9, 119–128.
- Jack, C. R. Jr, Petersen, R. C., Xu, Y. C., Waring, S. C., O'Brien, P. C., Tangalos, E. G., et al. (1997). Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. *Neurology*, 49, 786–794.
- Jacobs, B., Driscoll, L. & Schall, M. (1997). Life-span dendritic and spine changes in areas 10 and 18 of human cortex: A quantitative Golgi study. *Journal of Comparative Neurology*, 386, 661–680.
- Jagust, W. (2013). Vulnerable neural systems and the borderland of brain aging and neurodegeneration. *Neuron*, 77, 219–234.
- Jagust, W. J. & Mormino, E. C. (2011). Lifespan brain activity, beta-amyloid, and Alzheimer's disease. *Trends in Cognitive Sciences*, 15, 520–526.
- Ji, Z. S., Mullendorff, K., Cheng, I. H., Miranda, R. D., Huang, Y. & Mahley, R. W. (2006). Reactivity of apolipoprotein E4 and amyloid beta peptide: Lysosomal stability and neurodegeneration. *Journal of Biological Chemistry*, 281, 2683–2692.
- Jonsson, T. & Stefansson, K. (2013). TREM2 and neurodegenerative disease. *New England Journal of Medicine*, 369, 1568–1569.

- Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., *et al.* (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. *New England Journal of Medicine*, *368*, 107–116.
- Kawas, C., Gray, S., Brookmeyer, R., Fozard, J. & Zonderman, A. (2000). Age-specific incidence rates of Alzheimer's disease: The Baltimore Longitudinal Study of Aging. *Neurology*, *54*, 2072–2077.
- Khachaturian, Z. S. (2011). Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia*, *7*, 253–256.
- Knickmeyer, R. C., Wang, J., Zhu, H., Geng, X., Woolson, S., Hamer, R. M., *et al.* (2013). Common Variants in Psychiatric Risk Genes Predict Brain Structure at Birth. *Cerebral Cortex*, doi:10.1093/cercor/bhs401 [Epub ahead of print].
- Knopman, D. S., Jack, C. R. Jr, Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., *et al.* (2012). Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. *Annals of neurology*, doi:10.1002/ana.23816 [Epub ahead of print].
- Koivisto, K., Reinikainen, K. J., Hanninen, T., Vanhanen, M., Helkala, E. L., Mykkanen, L., *et al.* (1995). Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. *Neurology*, *45*, 741–747.
- Lambert, J. C., Heath, S., Even, G., Campion, D., Slegers, K., Hiltunen, M., *et al.* (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nature Genetics*, *41*, 1094–1099.
- Landau, S. M., Marks, S. M., Mormino, E. C., Rabinovici, G. D., Oh, P., O'Neil, J. P., *et al.* (2012). Association of lifetime cognitive engagement and low beta-amyloid deposition. *Archives of Neurology*, *69*, 623–629.
- Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nature Reviews Neurology*, *9*, 106–118.
- Mahley, R. W., Weisgraber, K. H. & Huang, Y. (2006). Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. *Proceedings of the National Academy of Sciences USA*, *103*, 5644–5651.
- Mauch, D. H., Nagler, K., Schumacher, S., Goritz, C., Muller, E. C., Otto, A. & Pfrieger, F. W. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. *Science*, *294*, 1354–1357.
- Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., *et al.* (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science*, *330*, 1774.
- McDonald, C. R., McEvoy, L. K., Gharapetian, L., Fennema-Notestine, C., Hagler, D. J. Jr, Holland, D., *et al.* (2009). Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. *Neurology*, *73*, 457–465.
- McEvoy, L. K., Fennema-Notestine, C., Roddey, J. C., Hagler, D. J. Jr, Holland, D., Karow, D. S., *et al.* (2009). Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. *Radiology*, *251*, 195–205.
- McEvoy, L. K., Holland, D., Hagler, D. J. Jr, Fennema-Notestine, C., Brewer, J. B. & Dale, A. M. (2011). Mild cognitive impairment: Baseline and longitudinal structural MR imaging measures improve predictive prognosis. *Radiology*, *259*, 834–843.
- Melka, M. G., Gillis, J., Bernard, M., Abrahamowicz, M., Chakravarty, M. M., Leonard, G. T., *et al.* (2013). FTO, obesity and the adolescent brain. *Human Molecular Genetics*, *22*, 1050–1058.
- Members, E. C. C., Brayne, C., Ince, P. G., Keage, H. A., McKeith, I. G., Matthews, F. E., *et al.* (2010). Education, the brain and dementia: Neuroprotection or compensation? *Brain*, *133*, 2210–2216.
- Mesulam, M. M. (1999). Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles. *Neuron*, *24*, 521–529.
- Mitter, S. S., Oria, R. B., Kvalsund, M. P., Pamplona, P., Joventino, E. S., Mota, R. M., *et al.* (2012). Apolipoprotein E4 influences growth and cognitive responses to micronutrient supplementation in shantytown children from northeast Brazil. *Clinics (Sao Paulo)*, *67*, 11–18.
- Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L. & Jagust, W. J. (2012). Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. *NeuroImage*, *59*, 1152–1160.
- Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M. & Mintun, M. A. (2010). APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Annals of Neurology*, *67*, 122–131.
- Mu, Y. & Gage, F. H. (2011). Adult hippocampal neurogenesis and its role in Alzheimer's disease. *Molecular Neurodegeneration*, *6*, 85. doi:10.1186/1750-1326-6-85.
- Negash, S., Greenwood, P. M., Sunderland, T., Parasuraman, R., Geda, Y. E., Knopman, D. S., *et al.* (2009). The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. *Neuropsychology*, *23*, 81–89.
- Neill, D. (1995). Alzheimer's disease: Maladaptive synaptostatic hypothesis. *Neurodegeneration*, *4*, 217–232.
- Neill, D. (2012). Should Alzheimer's disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence. *Ageing Research Reviews*, *11*, 104–122.
- Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., *et al.* (2011). Alzheimer's disease is not "brain aging": Neuropathological, genetic, and epidemiological human studies. *Acta neuropathologica*, *121*, 571–587.
- Nyberg, L., Lovden, M., Riklund, K., Lindenberg, U. & Backman, L. (2012). Memory aging and brain maintenance. *Trends in Cognitive Sciences*, *16*, 292–305.
- Nyberg, L., Salami, A., Andersson, M., Eriksson, J., Kalpouzos, G., Kauppi, K., *et al.* (2010). Longitudinal evidence for diminished frontal cortex function in aging. *Proceedings of the National Academy of Sciences USA*, *107*, 22682–22686.
- Oria, R. B., Costa, C. M., Lima, A. A., Patrick, P. D. & Guerrant, R. L. (2009). Semantic fluency: A sensitive marker for cognitive impairment in children with heavy diarrhea burdens? *Medical Hypotheses*, *73*, 682–686.
- Oria, R. B., Patrick, P. D., Zhang, H., Lorntz, B., de Castro Costa, C. M., Brito, G. A., *et al.* (2005). APOE4 protects the cognitive development in children with heavy diarrhea burdens in Northeast Brazil. *Pediatric Research*, *57*, 310–316.
- Paloneva, J., Mandelin, J., Kiialainen, A., Bohling, T., Prudlo, J., Hakola, P., *et al.* (2003). DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. *Journal of Experimental Medicine*, *198*, 669–675.
- Park, D. C. & Reuter-Lorenz, P. (2009). The adaptive brain: Aging and neurocognitive scaffolding. *Annual Review of Psychology*, *60*, 173–196.
- Persson, J., Lind, J., Larsson, A., Ingvar, M., Cruets, M., Van Broeckhoven, C., *et al.* (2006). Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? *Neurology*, *66*, 1029–1033.
- Pfefferbaum, A., Rohlfing, T., Rosenbloom, M. J., Chu, W., Colrain, I. M. & Sullivan, E. V. (2013). Variation in longitudinal trajectories of regional brain volumes of healthy men and women (ages 10 to 85 years) measured with atlas-based parcellation of MRI. *NeuroImage*, *65*, 176–193.
- Raber, J., Huang, Y. & Ashford, J. W. (2004). ApoE genotype accounts for the vast majority of AD risk and AD pathology. *Neurobiology of Aging*, *25*, 641–650.
- Rajagopalan, P., Hibar, D. P. & Thompson, P. M. (2013). TREM2 and neurodegenerative disease. *New England Journal of Medicine*, *369*, 1565–1567.
- Rakic, P. (2004). Neuroscience: Immigration denied. *Nature*, *427*, 685–686.
- Rapoport, S. I. & Nelson, P. T. (2011). Biomarkers and evolution in Alzheimer disease. *Progress in Neurobiology*, *95*, 510–513.

- Raz, N., Ghisletta, P., Rodrigue, K. M., Kennedy, K. M. & Lindenberger, U. (2010). Trajectories of brain aging in middle-aged and older adults: Regional and individual differences. *NeuroImage*, *51*, 501–511.
- Raz, N. & Lindenberger, U. (2010). News of cognitive cure for age-related brain shrinkage is premature: A comment on Burgmans *et al.* (2009). *Neuropsychology*, *24*, 255–257.
- Raz, N. & Lindenberger, U. (2011). Only time will tell: Cross-sectional studies offer no solution to the age-brain-cognition triangle: comment on Salthouse (2011). *Psychological Bulletin*, *137*, 790–795.
- Raz, N., Lindenberger, U., Rodrigue, K. M., Kennedy, K. M., Head, D., Williamson, A., *et al.* (2005). Regional brain changes in aging healthy adults: General trends, individual differences and modifiers. *Cerebral Cortex*, *15*, 1676–1689.
- Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D. & Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. *Proceedings of the National Academy of Sciences USA*, *98*, 3334–3339.
- Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., *et al.* (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. *New England Journal of Medicine*, *334*, 752–758.
- Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., *et al.* (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proceedings of the National Academy of Sciences USA*, *101*, 284–289.
- Reinvang, I., Espeseth, T. & Westlye, L. T. (2013). APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. *Neuroscience & Biobehavioral Reviews*, *37*, 1322–1335.
- Reinvang, I., Winjevoll, I. L., Rootwelt, H. & Espeseth, T. (2010). Working memory deficits in healthy APOE epsilon 4 carriers. *Neuropsychologia*, *48*, 566–573.
- Reitz, C., Tosto, G., Mayeux, R., Luchsinger, J. A., Group, N.-L. N. F. S. & Alzheimer's Disease Neuroimaging, I (2012). Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease. *PLoS One*, *7*, e50354.
- Rosnick, S. M., Pham, D. L., Kraut, M. A., Zonderman, A. B. & Davatzikos, C. (2003). Longitudinal magnetic resonance imaging studies of older adults: A shrinking brain. *The Journal of Neuroscience*, *23*, 3295–3301.
- Robakis, N. K. (2010). Are Abeta and its derivatives causative agents or innocent bystanders in AD? *Neuro-degenerative Diseases*, *7* 32–37.
- Rosen, V. M., Bergeson, J. L., Putnam, K., Harwell, A. & Sunderland, T. (2002). Working memory and apolipoprotein E: What's the connection? *Neuropsychologia*, *40*, 2226–2233.
- Sanders, J., Cowansage, K., Baumgartel, K. & Mayford, M. (2012). Elimination of dendritic spines with long-term memory is specific to active circuits. *The Journal of Neuroscience*, *32*, 12570–12578.
- Shaw, P., Lerch, J. P., Pruessner, J. C., Taylor, K. N., Rose, A. B., Greenstein, D., *et al.* (2007). Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. *Lancet Neurology*, *6*, 494–500.
- Sliwinski, M. & Buschke, H. (1999). Cross-sectional and longitudinal relationships among age, cognition, and processing speed. *Psychology & Aging*, *14*, 18–33.
- Small, B. J., Rosnick, C. B., Fratiglioni, L. & Backman, L. (2004). Apolipoprotein E and cognitive performance: A meta-analysis. *Psychology and Aging*, *19*, 592–600.
- Sojkova, J., Zhou, Y., An, Y., Kraut, M. A., Ferrucci, L., Wong, D. F. & Resnick, S. M. (2011). Longitudinal patterns of -amyloid deposition in nondemented older adults. *Archives of Neurology*, *68*, 644–649.
- Stern, Y. (2006). Cognitive reserve and Alzheimer disease. *Alzheimer Disease and Associated Disorders*, *20*, 112–117.
- Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer's disease. *Lancet Neurology*, *11*, 1006–1012.
- Stern, Y., Albert, S., Tang, M. X. & Tsai, W. Y. (1999). Rate of memory decline in AD is related to education and occupation: cognitive reserve? *Neurology*, *53*, 1942–1947.
- Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S. & Roses, A. D. (1993). Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proceedings of the National Academy of Sciences USA*, *90*, 1977–1981.
- Trachtenberg, A. J., Filippini, N., Ebmeier, K. P., Smith, S. M., Karpe, F. & Mackay, C. E. (2012). The effects of APOE on the functional architecture of the resting brain. *NeuroImage*, *59*, 565–572.
- Valenzuela, M. J., Sachdev, P., Wen, W., Chen, X. & Brodaty, H. (2008). Lifespan mental activity predicts diminished rate of hippocampal atrophy. *PLoS one*, *3*, e2598.
- Van Hoesen, G. W., Hyman, B. T. & Damasio, A. R. (1991). Entorhinal cortex pathology in Alzheimer's disease. *Hippocampus*, *1*, 1–8.
- Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Roberts, R. O., Lowe, V. J., *et al.* (2012). Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. *Annals of neurology*, *72*, 730–738.
- Verghese, P. B., Castellano, J. M. & Holtzman, D. M. (2011). Apolipoprotein E in Alzheimer's disease and other neurological disorders. *Lancet Neurology*, *10*, 241–252.
- Walhovd, K. B., Fjell, A. M., Brown, T. T., Kuperman, J. M., Chung, Y., Hagler, D. J. Jr, *et al.* (2012). Long-term influence of normal variation in neonatal characteristics on human brain development. *Proceedings of the National Academy of Sciences USA*, *109*, 20089–20094.
- Walhovd, K. B., Westlye, L. T., Amlie, I., Espeseth, T., Reinvang, I., Raz, N., *et al.* (2011). Consistent neuroanatomical age-related volume differences across multiple samples. *Neurobiology of Aging*, *32*, 916–932.
- Westlye, L. T., Reinvang, I., Rootwelt, H. & Espeseth, T. (2012). Effects of APOE on brain white matter microstructure in healthy adults. *Neurology*, *79*, 1961–1969.
- Wisdom, N. M., Callahan, J. L. & Hawkins, K. A. (2011). The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. *Neurobiology of Aging*, *32*, 63–74.
- Yu, L., Boyle, P. A., Leurgans, S., Schneider, J. A. & Bennett, D. A. (2014). Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. *Neurobiology of aging*, *35*, 819–826.
- Zatorre, R. J., Fields, R. D. & Johansen-Berg, H. (2012). Plasticity in gray and white: neuroimaging changes in brain structure during learning. *Nature Neuroscience*, *15*, 528–536.

Received 14 November 2013, accepted 22 January 2014